The University of Chicago Header Logo

Connection

Russell Z. Szmulewitz to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Russell Z. Szmulewitz has written about Prostatic Neoplasms.
Russell Z. Szmulewitz
Connection Strength
2.983
Prostatic Neoplasms
  1. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 2022 09; 82(13):1237-1247.
    View in: PubMed
    Score: 0.384
  2. Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med. 2015 Sep 16; 7(305):305ps19.
    View in: PubMed
    Score: 0.241
  3. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014 Nov 26; 12:313.
    View in: PubMed
    Score: 0.228
  4. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7.
    View in: PubMed
    Score: 0.222
  5. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89.
    View in: PubMed
    Score: 0.217
  6. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 01; 72(2):157-64.
    View in: PubMed
    Score: 0.178
  7. MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer. 2012 Feb 01; 130(3):509-20.
    View in: PubMed
    Score: 0.178
  8. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103.
    View in: PubMed
    Score: 0.153
  9. Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules. 2023 Aug 13; 28(16).
    View in: PubMed
    Score: 0.104
  10. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 08; 84(2):229-241.
    View in: PubMed
    Score: 0.102
  11. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 05 20; 40(15):1616-1622.
    View in: PubMed
    Score: 0.095
  12. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022 02; 25(2):274-282.
    View in: PubMed
    Score: 0.091
  13. A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640.
    View in: PubMed
    Score: 0.089
  14. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer. 2021 06 01; 127(11):1827-1835.
    View in: PubMed
    Score: 0.088
  15. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050.
    View in: PubMed
    Score: 0.084
  16. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 11 10; 37(32):2974-2986.
    View in: PubMed
    Score: 0.079
  17. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res. 2018 08 01; 24(15):3668-3680.
    View in: PubMed
    Score: 0.072
  18. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate. 2014 Nov; 74(15):1530-43.
    View in: PubMed
    Score: 0.056
  19. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91.
    View in: PubMed
    Score: 0.056
  20. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8.
    View in: PubMed
    Score: 0.054
  21. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013; 8(1):e53701.
    View in: PubMed
    Score: 0.050
  22. A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer. Eur Urol. 2012 Nov; 62(5):864-6.
    View in: PubMed
    Score: 0.049
  23. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
    View in: PubMed
    Score: 0.046
  24. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. Semin Oncol. 2011 Apr; 38(2):309-25.
    View in: PubMed
    Score: 0.044
  25. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. J Pharmacol Exp Ther. 2020 09; 374(3):438-451.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.